MA71551A - Composés macrocycles pour le traitement du cancer - Google Patents
Composés macrocycles pour le traitement du cancerInfo
- Publication number
- MA71551A MA71551A MA71551A MA71551A MA71551A MA 71551 A MA71551 A MA 71551A MA 71551 A MA71551 A MA 71551A MA 71551 A MA71551 A MA 71551A MA 71551 A MA71551 A MA 71551A
- Authority
- MA
- Morocco
- Prior art keywords
- cancer treatment
- macrocycle compounds
- macrocycle
- compounds
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022106792 | 2022-07-20 | ||
| CN2022128979 | 2022-11-01 | ||
| CN2023070766 | 2023-01-05 | ||
| CN2023087631 | 2023-04-11 | ||
| PCT/EP2023/069851 WO2024017859A1 (fr) | 2022-07-20 | 2023-07-18 | Composés macrocycles pour le traitement du cancer |
| EP23748009.0A EP4558507B1 (fr) | 2022-07-20 | 2023-07-18 | Composés macrocycles pour le traitement du cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71551A true MA71551A (fr) | 2025-05-30 |
Family
ID=87514141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71551A MA71551A (fr) | 2022-07-20 | 2023-07-18 | Composés macrocycles pour le traitement du cancer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20250268894A1 (fr) |
| EP (1) | EP4558507B1 (fr) |
| JP (1) | JP2025525565A (fr) |
| KR (1) | KR20250034953A (fr) |
| CN (1) | CN119585284A (fr) |
| AR (1) | AR129934A1 (fr) |
| AU (1) | AU2023311244A1 (fr) |
| CA (1) | CA3261063A1 (fr) |
| CL (1) | CL2025000081A1 (fr) |
| CO (1) | CO2025001184A2 (fr) |
| CR (1) | CR20250017A (fr) |
| IL (1) | IL316706A (fr) |
| MA (1) | MA71551A (fr) |
| MX (1) | MX2025000642A (fr) |
| PE (1) | PE20250850A1 (fr) |
| TW (1) | TWI860785B (fr) |
| WO (1) | WO2024017859A1 (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| KR20250085767A (ko) | 2022-09-29 | 2025-06-12 | 광조우 조요 파마테크 컴퍼니 리미티드 | 거대고리 유도체 및 이의 적용 |
| CN120813588A (zh) | 2023-02-14 | 2025-10-17 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的三环化合物 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (fr) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2025217307A1 (fr) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Procédés de prédiction de la réponse à un inhibiteur de ras(on) et polythérapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (fr) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras |
| WO2025265060A1 (fr) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Compositions thérapeutiques et procédés de gestion d'effets liés au traitement |
| WO2026006747A1 (fr) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026015740A1 (fr) * | 2024-07-11 | 2026-01-15 | Treeline Biosciences, Inc. | Inhibiteurs de ras macrocycliques |
| WO2026015801A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble liés à ras |
| WO2026015790A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026015796A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Méthodes de traitement d'une maladie ou d'un trouble lié à ras |
| WO2026015825A1 (fr) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas |
| WO2026050446A1 (fr) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2026072904A2 (fr) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions et méthodes de traitement du cancer du poumon |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220218852A1 (en) | 2019-04-18 | 2022-07-14 | Provincial Health Services Authority | Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy |
| AU2020377925A1 (en) * | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| CA3194067A1 (fr) * | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Derives d'indole servant d'inhibiteurs dans le traitement du cancer |
-
2023
- 2023-07-14 AR ARP230101857A patent/AR129934A1/es unknown
- 2023-07-18 KR KR1020257001146A patent/KR20250034953A/ko active Pending
- 2023-07-18 CN CN202380054201.7A patent/CN119585284A/zh active Pending
- 2023-07-18 EP EP23748009.0A patent/EP4558507B1/fr active Active
- 2023-07-18 JP JP2025502539A patent/JP2025525565A/ja active Pending
- 2023-07-18 PE PE2025000193A patent/PE20250850A1/es unknown
- 2023-07-18 IL IL316706A patent/IL316706A/en unknown
- 2023-07-18 AU AU2023311244A patent/AU2023311244A1/en active Pending
- 2023-07-18 WO PCT/EP2023/069851 patent/WO2024017859A1/fr not_active Ceased
- 2023-07-18 CA CA3261063A patent/CA3261063A1/fr active Pending
- 2023-07-18 CR CR20250017A patent/CR20250017A/es unknown
- 2023-07-18 MA MA71551A patent/MA71551A/fr unknown
- 2023-07-19 TW TW112126951A patent/TWI860785B/zh active
-
2025
- 2025-01-13 CL CL2025000081A patent/CL2025000081A1/es unknown
- 2025-01-16 US US19/025,165 patent/US20250268894A1/en active Pending
- 2025-01-16 MX MX2025000642A patent/MX2025000642A/es unknown
- 2025-01-31 CO CONC2025/0001184A patent/CO2025001184A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR129934A1 (es) | 2024-10-16 |
| EP4558507A1 (fr) | 2025-05-28 |
| CA3261063A1 (fr) | 2024-01-25 |
| CN119585284A (zh) | 2025-03-07 |
| IL316706A (en) | 2024-12-01 |
| WO2024017859A1 (fr) | 2024-01-25 |
| TWI860785B (zh) | 2024-11-01 |
| PE20250850A1 (es) | 2025-03-21 |
| JP2025525565A (ja) | 2025-08-05 |
| CL2025000081A1 (es) | 2025-03-28 |
| US20250268894A1 (en) | 2025-08-28 |
| TW202413378A (zh) | 2024-04-01 |
| KR20250034953A (ko) | 2025-03-11 |
| AU2023311244A1 (en) | 2024-11-14 |
| MX2025000642A (es) | 2025-03-07 |
| EP4558507B1 (fr) | 2026-04-29 |
| CO2025001184A2 (es) | 2025-02-13 |
| CR20250017A (es) | 2025-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA71551A (fr) | Composés macrocycles pour le traitement du cancer | |
| MA71370A (fr) | Inhibiteurs macrocycliques de kras pour le traitement du cancer | |
| IL314136A (en) | Imidazole macrocycles for the treatment of autoimmune disease | |
| MA71734A (fr) | Composés pour le traitement du cancer | |
| AU2024220916A1 (en) | Tricyclic compounds for the treatment of cancer | |
| MA56508A (fr) | Inhibiteur d'egfr pour le traitement du cancer | |
| EP4225749A4 (fr) | Composés et méthodes de traitement de cancers | |
| EP4467154A4 (fr) | Médicament pour le traitement ou la prévention du cancer | |
| MA43745A (fr) | Dérivés de 4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carbonitrile pour le traitement du cancer | |
| EP3908601A4 (fr) | Procédés et compositions pour le traitement du cancer | |
| EP4149547A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
| MA52412A (fr) | Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie | |
| IL289201A (en) | Compounds for the treatment of cancer | |
| EP3919059A4 (fr) | Composition pour le traitement d'une infection par acinetobacter baumannii résistante aux antibiotiques de type carbapénèmes | |
| EP4174087A4 (fr) | Médicament pour le traitement de tumeur | |
| EP4384220A4 (fr) | Compositions et méthodes de traitement du cancer | |
| EP3958980A4 (fr) | Nouveaux dérivés de triazolothiadiazine ciblés pour le traitement du cancer du poumon | |
| GB202010829D0 (en) | Compounds for treatment of neovascular diseases | |
| MA71446A (fr) | Molécules de liaison pour le traitement du cancer | |
| EP3923947A4 (fr) | Inhibiteurs de fgfr pour le traitement du cancer | |
| MA51856A (fr) | Composés pour le traitement du covid-19 | |
| EP4370137A4 (fr) | Protoporphyrine métallique pour le traitement du virus bk | |
| EP3962921A4 (fr) | Androgènes à coumarine modifiée pour le traitement du cancer de la prostate | |
| EP3965804A4 (fr) | Compositions de bêta-lactamase pour le traitement de la maladie du greffon contre l'hôte | |
| EP4334463A4 (fr) | Entité biologique pour le traitement du cancer du cerveau |